Evidence map›Paper›PMID 29766216›Full record

ArticleIntensive care medicine2018

Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.

Etienne Gayat, Alexa Hollinger, Alain Cariou, Nicolas Deye, Antoine Vieillard-Baron, Samir Jaber, Benjamin G Chousterman, Qin Lu, Pierre François Laterre, Xavier Monnet and 10 more

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Intensive care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01367093 completednot on this map

French and EuRopean Outcome Registry in Intensive Care Unit

TypeobservationalSponsorAssistance Publique - Hôpitaux de ParisRan2011 to 2015Enrolled2,137ConditionsIntensive Care Unit Syndrome, Tracheal Intubation Morbidity
NCT05272878 phase3active not recruitingnot on this mapstarted 2022, after this paper: background citation

Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU "START-or-NOT Trial". A Prospective, Randomized, Double Blinded, Multicenter Study

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2022 to 2026Enrolled508ConditionsAcute Kidney InjuryArmsIRBESARTAN, tablet, 150 mg, Placebo, tablet, 150 mg
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 91 citations in OpenAlex.

  1. Review
  2. Article
  3. SGLT2 Inhibitors and Long-Term Outcomes After AKI.Kidney international reports · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Role of G protein coupled receptors in acute kidney injury.Cell communication and signaling : CCS · 2024
    Review
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Integrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 3 countries.

Etienne GayatDepartment of Anaesthesiology, Critical Care Medicine and Burn Unit, Saint Louis and Lariboisière University Hospitals, AP-HP, 2 rue A. Paré, 75010, Paris, France.
Alexa HollingerDepartment of Anaesthesiology, Critical Care Medicine and Burn Unit, Saint Louis and Lariboisière University Hospitals, AP-HP, 2 rue A. Paré, 75010, Paris, France.
Alain CariouMedical Intensive Care Unit, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Nicolas DeyeInstitut National de la Santé et de la Recherche Médicale (INSERM), Lariboisière Hospital and INI-CRCT Network, INSERM UMR-S942, Paris, France.
Antoine Vieillard-BaronIntensive Care Unit, University Hospital Ambroise Paré, Assistance Publique-Hopitaux de Paris, 26930, Boulogne-Billancourt, France.
Samir JaberIntensive Care Unit, Anaesthesia and Critical Care Department, Saint Eloi Teaching Hospital, Centre Hospitalier Universitaire Montpellier, Montpellier University, Montpellier, France.
Benjamin G ChoustermanDepartment of Anaesthesiology, Critical Care Medicine and Burn Unit, Saint Louis and Lariboisière University Hospitals, AP-HP, 2 rue A. Paré, 75010, Paris, France.
Qin LuMultidisciplinary Intensive Care Unit, Department of Anesthesiology and Critical Care Medicine, La Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, UPMC Paris 6, Paris, France.
Pierre François LaterreDepartment of Critical Care Medicine, Saint Luc University Hospital, Université Catholique de Louvain, Avenue Hippocrate 10, 1200, Brussels, Belgium.
Xavier MonnetMedical Intensive Care Unit, Bicêtre Hospital, Paris-Sud University Hospitals, Inserm UMR_S999, Paris-Sud University, Le Kremlin-Bicêtre, France.
Michael DarmonMedical ICU, St-Louis Hospital, Université Paris Sorbonne Cité, Paris Diderot, Assistance Publique des Hôpitaux de Paris, Paris, France.
Marc LeoneService d'anesthésie et de réanimation, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Aix Marseille Université, Marseille, France.
Bertrand GuidetService de Réanimation Médicale, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
Romain SonnevilleMedical ICU, Bichat Hospital, Université Paris Sorbonne Cité, Paris Diderot, Assistance Publique des Hôpitaux de Paris, Paris, France.
Jean-Yves LefrantDepartment of Anesthesiology, Critical Care, Emergency and Pain Medicine, Nimes University Hospital, 30029, Nîmes, France.
Marie-Céline FournierDepartment of Anaesthesiology, Critical Care Medicine and Burn Unit, Saint Louis and Lariboisière University Hospitals, AP-HP, 2 rue A. Paré, 75010, Paris, France.
Matthieu Resche-RigonECSTRA Team, INSERM, Service de biostatistique et information Médicale, Hôpitaux Universitaires St-Louis-Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot-Paris 7, Sorbonne Paris Cité, Paris, France.
Alexandre MebazaaDepartment of Anaesthesiology, Critical Care Medicine and Burn Unit, Saint Louis and Lariboisière University Hospitals, AP-HP, 2 rue A. Paré, 75010, Paris, France.
Matthieu LegrandDepartment of Anaesthesiology, Critical Care Medicine and Burn Unit, Saint Louis and Lariboisière University Hospitals, AP-HP, 2 rue A. Paré, 75010, Paris, France. matthieu.legrand@aphp.fr.ORCID http://orcid.org/0000-0001-9788-5316
FROG-ICU investigators
Inserm · FRDélégation Paris 7 · FRUniversité Paris-Sud · FRAix-Marseille Université · FRCliniques Universitaires Saint-Luc · BESorbonne Université · FRUniversité de Montpellier · FR

Funding

Programme Hospitalier de la Recherche Clinique AON 10-216
6 · The paper itself

Abstract

purposeAcute kidney injury (AKI) is associated with the activation of the renin-angiotensin system. Whether angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB) improve outcome in patients recovering from AKI remains unexplored. The purpose was to investigate the association between prescription of ACEi/ARB at intensive care unit (ICU) discharge and 1-year outcome in patients recovering from AKI.

methodsAssociation between ACEi/ARB and 1-year mortality rate was explored in 1551 patients discharged from 21 European ICUs in an observational cohort. One-year all-cause mortality after ICU discharge was the primary endpoint. AKI was defined using the kidney disease improvement global outcome definition. Propensity score matching was used to consider the probability to receive ACEi/ARB at ICU discharge and included chronic heart failure, ACEi/ARB on ICU admission, Charlson Comorbidity Index, age, diabetes mellitus, chronic kidney disease, estimated glomerular filtration rate and arterial blood pressure at ICU discharge vasopressors and renal replacement therapy.

resultsOverall, 1-year mortality was 28 and 15% in patients with AKI (n = 611, 39%) and without AKI (n = 940), respectively. In patients with AKI, unadjusted, adjusted and propensity-score matched 1-year mortality rates were lower in patients treated with ACEi/ARB at ICU discharge [HR of 0.55 (0.35-0.89), HR of 0.45 (0.27-0.75), and HR of 0.48 (0.27-0.85, p < 0.001), respectively]. These results were consistent across sensitivity analysis. No association was observed in patients without AKI.

conclusionsIn patients discharged alive from the ICU after experiencing AKI, ACEi/ARB prescription at discharge is associated with a decrease in 1-year mortality.

trial registrationClinicalTrials.gov NCT01367093. Registered on 6 June 2011.

Indexed as

Drug-Related Side Effects and Adverse ReactionsAcute Kidney InjuryAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCohort StudiesFemaleHumansMaleMiddle AgedRenal Insufficiency, ChronicAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAcute kidney injuryAngiotensin-converting enzyme inhibitorsAngiotensin-receptor blockersCritically IllICUICU dischargeMortality

Identifiers

PMID29766216
OpenAlexW2803977650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.